Synthesis and In-vitro antibacterial activity of 5-substituted 1-methyl-4-nitro-1H-imidazoles

Archiv der Pharmazie

Volumn 341, Issue 8, 2008, Pages 497-501

  Letafat, Bahram ^a   Emami, Saeed ^b   Aliabadi, Alireza ^c   Mohammadhosseini, Negar ^a,c   Moshafi, Mohammad Hassan ^d   Asadipour, Ali ^d   Shafiee, Abbas ^c   Foroumadi, Alireza ^c,d  

^a ISLAMIC AZAD UNIVERSITY   (Iran)

^b MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

4 Nitroimidazole; Antimicrobial activity; Helicobacter pylori; Synthesis

Indexed keywords

1 METHYL 4 NITRO 5 (4 METHYLPHENYLSULFONYL) 1H IMIDAZOLE; 1 METHYL 4 NITRO 5 (PHENYLSULFONYL) 1H IMIDAZOLE; 1 METHYL 4 NITRO 5 (PHENYLTHIO) 1H IMIDAZOLE; 1 METHYL 4 NITRO 5 [4 ACETAMIDO(PHENYLSULFONYL)] 1H IMIDAZOLE; 2 [(1 METHYL 4 NITRO 5 IMIDAZOLYL)SULFONYL] 5 (4 METHOXYPHENYL) 1,3,4 THIADIAZOLE; 2 [(1 METHYL 4 NITRO 5 IMIDAZOLYL)THIO] 5 (1 METHYL 5 NITRO 2 IMIDAZOLYL) 1,3,4 THIADIAZOLE; 2 [(1 METHYL 4 NITRO 5 IMIDAZOLYL)THIO] 5 (4 METHOXYPHENYL) 1,3,4 THIADIAZOLE; 2 [(1 METHYL 4 NITRO 5 IMIDAZOLYL)THIO] 5 (5 NITROFURAN 2 YL) 1,3,4 THIADIAZOLE; 2 [(1 METHYL 4 NITRO 5 IMIDAZOLYL)THIO] 5 ACETAMIDO 1,3,4 THIADIAZOLE; IMIDAZOLE DERIVATIVE; METRONIDAZOLE; NORFLOXACIN; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; NITROIMIDAZOLE DERIVATIVE;

AGAR DILUTION; ANTIBACTERIAL ACTIVITY; ARTICLE; BACILLUS SUBTILIS; BACTERIAL GROWTH; CONTROLLED STUDY; DRUG STRUCTURE; DRUG SYNTHESIS; ENTEROBACTER AEROGENES; ESCHERICHIA COLI; GROWTH INHIBITION; HELICOBACTER PYLORI; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; BACTERIAL COUNT; DRUG EFFECT; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; MICROBIOLOGICAL EXAMINATION; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANTI-BACTERIAL AGENTS; COLONY COUNT, MICROBIAL; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; MICROBIAL SENSITIVITY TESTS; NITROIMIDAZOLES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 53149101347     PISSN: 03656233     EISSN: 15214184     Source Type: Journal    
DOI: 10.1002/ardp.200800022     Document Type: Article

References (21)

1. R. Tripathi, N. Tewari, N. Dwivedi, V. K. Tiwari, Med. Res. Rev. 2005, 25, 93-131.
2. S. Suerbaum, P. Michetti, N. Engl. J. Med. 2002, 347, 1175-1186.
3. A. Mohar, C. Ley, J. Guarner, R. Herrera-Goepfert, et al., Am. J. Gastroenterol. 2002, 97, 2530-2535.
4. A. Foroumadi, F. Soltani, H. Moallemzadeh-Haghighi, A. Shafiee, Arch. Pharm. (Weinheim) 2005, 338, 112-116.
5. A. Foroumadi, Z. Kargar, A. Sakhteman, Z. Sharifzadeh, et al., Bioorg. Med. Chem. Lett. 2006, 16, 1164-1167.
6. J. Mirzaei, F. Siavoshi, S. Emami, F. Safari, et al., Eur. J. Med. Chem. 2007, in press, doi:10.1016/j.ejmech.2007.11.019.
7. A. Foroumadi, S. Pournourmohammadi, F. Soltani, M. Asgharian-Rezaee, et al., Bioorg. Med. Chem. Lett. 2005, 15, 1983-1985.
8. M. Bertinaria, U. Galli, G. Sorba, R. Fruttero, et al., Drug Dev. Res. 2003, 60, 225-239.
9. A. Buschini, F. Giordani, C. N. de Albuquerque, C. Pellacani, et al., Biochem. Pharmacol. 2007, 73, 1537-1547.
10. N. A. Al-Masoudi, Y. A. Al-Soud, A. Kalogerakis, C. Pannecouque, E. de Clercq, Chem. Biodivers. 2006, 3, 515-526.
11. J. Suwinski, W. Szczepankiewicz, M. Widel, Arch. Pharm. (Weinheim) 1992, 325, 317-324.
12. A. Foroumadi, A. Sakhteman, Z. Sharifzadeh, N. Mohammadhosseini, et al., Daru 2007, 15, 218-226.
13. A. Foroumadi, S. Mansouri, S. Emami, J. Mirzaei, et al., Arch. Pharm. (Weinheim) 2006, 339, 621-624.
14. I. E. Balaban, F. L. Pyman, J. Chem. Soc. 1922, 121, 947-958.
15. G. B. Barlin, J. Chem. Soc. 1967, 641-647.
16. S. Kulkarni, M. Ross Grimmett, Aust. J. Chem. 1987, 40, 1415-1425.
17. L. L. Bennet, H. T. Barry, J. Am. Chem. Soc. 1957, 79, 2188-2191.
18. th Ed., The C. V. Mosby Company, St. Louis, MO, USA, 2002, pp. 235-236.
19. S. Demirayak, K. Benkli, K. Güven, Eur. J. Med. Chem. 2000, 35, 1037-1040.
20. A. Foroumadi, N. Mohammadhosseini, S. Emami, B. Letafat, et al., Arch. Pharm. (Weinheim) 2007, 340, 47-52.
21. National Committee for Clinical Laboratory Standards 2004. Methods for Antimicrobial Susceptibility Testing of Anaerobic bacteria. Approved standard M11-A6. 6th ed. National Committee for Clinical Laboratory Standards, Villanova, PA, USA